Fintel reports that on January 14, 2025, Craig-Hallum initiated coverage of LifeVantage (NasdaqCM:LFVN) with a Buy recommendation.
Analyst Price Forecast Suggests 3.07% Upside
As of December 23, 2024, the average one-year price target for LifeVantage is $26.52/share. The forecasts range from a low of $26.26 to a high of $27.30. The average price target represents an increase of 3.07% from its latest reported closing price of $25.73 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for LifeVantage is 231MM, an increase of 17.77%. The projected annual non-GAAP EPS is 0.66.
What is the Fund Sentiment?
There are 105 funds or institutions reporting positions in LifeVantage. This is an increase of 14 owner(s) or 15.38% in the last quarter. Average portfolio weight of all funds dedicated to LFVN is 0.02%, an increase of 83.94%. Total shares owned by institutions increased in the last three months by 28.67% to 3,935K shares. 
The put/call ratio of LFVN is 0.05, indicating a bullish outlook.
What are Other Shareholders Doing?
Renaissance Technologies holds 828K shares representing 6.61% ownership of the company. In its prior filing, the firm reported owning 855K shares , representing a decrease of 3.26%. The firm increased its portfolio allocation in LFVN by 61.56% over the last quarter.
Capital Management holds 420K shares representing 3.35% ownership of the company.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 290K shares representing 2.31% ownership of the company. No change in the last quarter.
Envestnet Asset Management holds 223K shares representing 1.78% ownership of the company. In its prior filing, the firm reported owning 1K shares , representing an increase of 99.41%. The firm increased its portfolio allocation in LFVN by 1,770.08% over the last quarter.
VEXMX - Vanguard Extended Market Index Fund Investor Shares holds 195K shares representing 1.56% ownership of the company. In its prior filing, the firm reported owning 196K shares , representing a decrease of 0.26%. The firm increased its portfolio allocation in LFVN by 74.31% over the last quarter.
Lifevantage Background Information
(This description is provided by the company.)
LifeVantage Corporation is a pioneer in Nutrigenomics - a new science dedicated to biohacking the human aging code. The Company engages in the identification, research, development and distribution of advanced nutraceutical dietary supplements and skin and hair care products, including its Protandim® product line, LifeVantage® Omega+ and ProBio dietary supplements, the TrueScience® line of Nrf2 infused skin care and hair care products, Petandim® for Dogs, Axio® smart energy drink mixes, and the PhysIQ™ weight management system. LifeVantage was founded in 2003 and is headquartered in Salt Lake City, Utah.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
